See more : NuVasive, Inc. (NUVA) Income Statement Analysis – Financial Results
Complete financial analysis of GeoVax Labs, Inc. (GOVXW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GeoVax Labs, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Suzhou Kelida Building& Decoration Co.,Ltd. (603828.SS) Income Statement Analysis – Financial Results
- Leo Systems, Inc. (5410.TWO) Income Statement Analysis – Financial Results
- UFTC (7714.TWO) Income Statement Analysis – Financial Results
- Sprott Physical Platinum and Palladium Trust (SPPP.TO) Income Statement Analysis – Financial Results
- Tonghua Grape Wine Co.,Ltd (600365.SS) Income Statement Analysis – Financial Results
GeoVax Labs, Inc. (GOVXW)
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 81.00K | 385.00K | 1.82M | 1.18M | 963.00K | 1.08M | 828.92K | 428.08K | 882.96K | 2.42M | 2.66M | 4.90M | 5.19M | 3.67M | 2.91M | 237.00K | 852.91K | 0.00 | 0.00 | 0.00 | 180.24K | 2.62M | 859.84K | 2.28M | 5.37M | 2.73M | 93.95K |
Cost of Revenue | 20.72M | 56.28K | 15.55M | 2.44M | 1.91M | 1.88M | 2.02M | 1.97M | 1.69M | 1.81M | 2.91M | 3.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.74M | 2.88M | 4.83M | 5.76M | 4.35M | 279.23K |
Gross Profit | -20.72M | 24.72K | -15.17M | -621.46K | -734.82K | -915.65K | -942.08K | -1.14M | -1.27M | -930.01K | -497.33K | -386.52K | 4.90M | 5.19M | 3.67M | 2.91M | 237.00K | 852.91K | 0.00 | 0.00 | 0.00 | 180.24K | -124.79K | -2.02M | -2.55M | -390.38K | -1.62M | -185.29K |
Gross Profit Ratio | 0.00% | 30.51% | -3,940.04% | -34.09% | -62.49% | -95.08% | -87.61% | -137.76% | -295.51% | -105.33% | -20.57% | -14.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | -4.76% | -234.44% | -112.09% | -7.27% | -59.17% | -197.22% |
Research & Development | 20.72M | 9.12M | 15.55M | 2.44M | 1.91M | 1.88M | 2.02M | 1.97M | 1.69M | 1.81M | 2.91M | 3.04M | 4.28M | 4.79M | 4.07M | 3.74M | 1.76M | 665.86K | 0.00 | 0.00 | 0.00 | 0.00 | 2.43M | 1.47M | 510.29K | 1.58M | 827.84K | 76.71K |
General & Administrative | 6.02M | 4.99M | 3.58M | 2.20M | 1.64M | 1.65M | 1.23M | 2.13M | 1.43M | 1.81M | 1.79M | 1.75M | 2.97B | 3.16M | 2.91M | 2.97M | 0.00 | 843.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | -74.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.97B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.95M | 4.99M | 3.58M | 2.20M | 1.64M | 1.65M | 1.23M | 2.13M | 1.43M | 1.81M | 1.79M | 1.75M | 2.97M | 3.16M | 2.91M | 2.97M | 2.78M | 843.34K | 875.81K | 1.55M | 676.64K | 0.00 | 4.74M | 4.04M | 4.17M | 3.27M | 1.48M | 1.01M |
Other Expenses | -20.65M | 7.00K | 176.00K | -141.00K | 0.00 | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 6.02M | 14.11M | 19.13M | 4.64M | 3.55M | 3.53M | 3.25M | 4.10M | 3.12M | 3.62M | 4.71M | 4.80M | 7.25M | 7.96M | 6.98M | 6.71M | 4.54M | 1.51M | 875.81K | 1.55M | 676.64K | 0.00 | 13.08M | 5.51M | 4.68M | 4.85M | 2.31M | 1.08M |
Cost & Expenses | 26.74M | 14.11M | 19.13M | 4.64M | 3.55M | 3.53M | 3.25M | 4.10M | 3.12M | 3.62M | 4.71M | 4.80M | 7.25M | 7.96M | 6.98M | 6.71M | 4.54M | 1.51M | 875.81K | 1.55M | 676.64K | 0.00 | 15.82M | 8.39M | 9.52M | 10.61M | 6.66M | 1.36M |
Interest Income | 776.18K | 7.44K | 4.74K | 2.27K | 6.36K | 5.21K | 4.29K | 1.67K | 5.47K | 4.06K | 4.55K | 4.00K | 2.22K | 23.51K | 31.08K | 73.20K | 62.51K | 72.13K | 0.00 | 0.00 | 0.00 | 0.00 | 226.06K | 83.36K | 0.00 | 76.84K | 0.00 | 10.00K |
Interest Expense | 0.00 | 0.00 | 1.29K | 143.52K | 4.50K | 2.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.13K | 337.24K | 554.89K | 0.00 | 274.41K | 1.37M | 0.00 | 968.41K | 0.00 | 2.31K |
Depreciation & Amortization | 74.17K | 56.28K | 38.52K | 19.66K | 8.35K | 19.80K | 28.03K | 28.78K | 28.94K | 69.04K | 78.86K | 93.64K | 109.02K | 119.77K | 89.78K | 61.01K | 54.46K | 49.10K | 470.59K | 269.59K | 519.17K | 0.00 | 1.63M | 827.35K | 1.10M | 318.41K | 93.67K | 33.46K |
EBITDA | -26.67M | -13.97M | -18.53M | -2.79M | -2.36M | -2.54M | -2.14M | -3.24M | -2.67M | -2.67M | -2.21M | -2.05M | -2.24M | -2.63M | -3.19M | -3.74M | -4.25M | -607.20K | -1.35M | -1.51M | -653.85K | 180.24K | -11.57M | -6.70M | -6.14M | -4.92M | -3.83M | -1.24M |
EBITDA Ratio | 0.00% | -17,319.75% | -4,869.09% | -154.53% | -200.51% | -266.15% | -199.62% | -391.42% | -622.74% | -302.23% | -91.25% | -80.50% | -45.72% | -51.13% | -87.93% | -128.53% | -1,793.15% | -71.19% | 0.00% | 0.00% | 0.00% | 100.00% | -441.70% | -779.59% | -269.25% | -91.69% | -140.45% | -1,315.47% |
Operating Income | -26.74M | -14.03M | -18.75M | -2.82M | -2.37M | -2.56M | -2.17M | -3.27M | -2.69M | -2.74M | -2.29M | -2.14M | -2.35M | -2.77M | -3.32M | -3.80M | -4.30M | -656.29K | -875.81K | -1.55M | -676.64K | 180.24K | -13.20M | -7.53M | -7.24M | -5.24M | -3.93M | -1.27M |
Operating Income Ratio | 0.00% | -17,319.75% | -4,869.09% | -154.53% | -201.76% | -266.15% | -202.22% | -394.90% | -629.50% | -310.05% | -94.70% | -80.50% | -47.94% | -53.44% | -90.38% | -130.62% | -1,816.13% | -76.95% | 0.00% | 0.00% | 0.00% | 100.00% | -503.93% | -875.82% | -317.58% | -97.62% | -143.88% | -1,351.09% |
Total Other Income/Expenses | 776.18K | 7.44K | 175.51K | -141.25K | 1.86K | 2.62K | 4.29K | 1.67K | 5.47K | 4.06K | 4.55K | 3.82K | 2.22K | 23.51K | 3.32M | 73.20K | 62.51K | 72.13K | 217.01K | 717.89K | -58.52K | -180.24K | -48.34K | -1.29M | -2.07M | -891.57K | -59.92K | -127.40K |
Income Before Tax | -25.97M | -14.02M | -18.57M | -2.96M | -2.37M | -2.56M | -2.17M | -3.27M | -2.69M | -2.73M | -2.28M | -2.14M | -2.35B | 0.00 | -3.28B | -3.73M | 0.00 | -584.17K | -1.41M | -1.66M | -735.16K | 0.00 | -13.25M | -8.82M | -9.31M | -6.13M | -3.99M | -1.40M |
Income Before Tax Ratio | 0.00% | -17,311.11% | -4,823.38% | -162.26% | -201.60% | -265.84% | -201.82% | -394.70% | -628.22% | -309.59% | -94.51% | -80.35% | -47,895.53% | 0.00% | -89,533.19% | -128.11% | 0.00% | -68.49% | 0.00% | 0.00% | 0.00% | 0.00% | -505.78% | -1,025.47% | -408.34% | -114.23% | -146.08% | -1,486.69% |
Income Tax Expense | 0.00 | -7.44K | -38.52K | -19.66K | 4.50K | 5.21K | 0.00 | 0.00 | 0.00 | 0.00 | 4.55K | -93.82K | 2.22M | -23.51K | 31.05M | 0.00 | -62.51K | 0.00 | 62.13K | 658.91K | 2.40M | 618.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -38.07M |
Net Income | -25.97M | -14.01M | -18.53M | -2.94M | -2.38M | -2.56M | -2.17M | -3.27M | -2.69M | -2.73M | -2.28M | -2.14M | -2.35M | -2.75M | -3.28M | -3.73M | -4.24M | -584.17K | -1.41M | -2.21M | -3.08M | -618.14K | -13.25M | -8.82M | -9.31M | -6.13M | -3.99M | 36.67M |
Net Income Ratio | 0.00% | -17,301.93% | -4,813.37% | -161.18% | -201.98% | -265.84% | -201.82% | -394.70% | -628.22% | -309.59% | -94.51% | -80.35% | -47.90% | -52.98% | -89.53% | -128.11% | -1,789.76% | -68.49% | 0.00% | 0.00% | 0.00% | -342.96% | -505.78% | -1,025.47% | -408.34% | -114.23% | -146.08% | 39,031.23% |
EPS | -10.22 | -5.52 | -7.30 | -1.16 | -0.94 | -1.01 | -0.85 | -1.29 | -1.06 | -1.08 | -0.90 | -0.84 | -0.92 | -1.08 | -1.29 | -1.47 | -1.67 | -0.23 | -0.55 | -0.87 | -1.21 | -0.24 | -5.22 | -3.47 | -3.66 | -2.41 | -1.57 | 14.44 |
EPS Diluted | -10.22 | -5.52 | -7.30 | -1.16 | -0.94 | -1.01 | -0.85 | -1.29 | -1.06 | -1.08 | -0.90 | -0.84 | -0.92 | -1.08 | -1.29 | -1.47 | -1.67 | -0.23 | -0.55 | -0.87 | -1.21 | -0.24 | -5.22 | -3.47 | -3.66 | -2.41 | -1.57 | 14.44 |
Weighted Avg Shares Out | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M |
Weighted Avg Shares Out (Dil) | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M | 2.54M |
Source: https://incomestatements.info
Category: Stock Reports